Research Analysts Offer Predictions for Alumis Q1 Earnings

Alumis Inc. (NASDAQ:ALMS) – Stock analysts at HC Wainwright decreased their Q1 2025 EPS estimates for shares of Alumis in a note issued to investors on Thursday, March 20th. HC Wainwright analyst M. Kapoor now expects that the company will earn ($1.29) per share for the quarter, down from their prior forecast of ($0.99). HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Alumis’ current full-year earnings is ($8.51) per share. HC Wainwright also issued estimates for Alumis’ Q2 2025 earnings at ($1.00) EPS, Q3 2025 earnings at ($1.01) EPS, Q4 2025 earnings at ($1.01) EPS and FY2025 earnings at ($4.26) EPS.

Several other equities analysts have also recently weighed in on the stock. Oppenheimer began coverage on shares of Alumis in a research note on Thursday, January 30th. They issued an “outperform” rating and a $32.00 target price for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Alumis in a research report on Thursday. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $26.00.

Alumis Price Performance

Shares of NASDAQ ALMS opened at $3.75 on Monday. Alumis has a 52 week low of $3.18 and a 52 week high of $13.53. The stock has a 50 day moving average price of $5.69 and a 200 day moving average price of $8.54.

Hedge Funds Weigh In On Alumis

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Foresite Capital Management VI LLC acquired a new stake in Alumis during the 4th quarter valued at approximately $33,033,000. Samsara BioCapital LLC acquired a new position in shares of Alumis during the third quarter valued at about $34,886,000. Geode Capital Management LLC bought a new position in Alumis in the third quarter worth approximately $3,266,000. Norges Bank bought a new position in shares of Alumis in the 4th quarter worth $1,606,000. Finally, Foresite Capital Management V LLC grew its holdings in shares of Alumis by 3.5% during the fourth quarter. Foresite Capital Management V LLC now owns 5,779,348 shares of the company’s stock valued at $45,426,000 after buying an additional 194,459 shares during the last quarter.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.